Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
danazol + iguratimod
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Danazol + iguratimod is a combination therapy consisting of two small molecule drugs, danazol and iguratimod. Danazol is a synthetic androgen with immunosuppressive properties, commonly used in the treatment of immune thrombocytopenia (ITP) and other autoimmune conditions. Iguratimod is an antirheumatic agent widely used in China and Japan for rheumatoid arthritis and has demonstrated immunomodulatory effects by modulating T-cell differentiation. The combination targets both platelet production (danazol) and immune-mediated platelet destruction (iguratimod), providing a synergistic "double-hit" mechanism for treating corticosteroid-resistant or relapsed ITP. Clinical studies have shown that this regimen achieves higher response rates compared to danazol monotherapy, with good tolerability[1][2][4].
- Other names
- danazol + iguratimod
02
Targets
CYP11B1 (Cytochrome P450 11B1)AR (Adrenergic receptors)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GR (Glucocorticoid receptor)MIF (Oxidized macrophage migration inhibitory factor)PR (Progesterone receptor)PKC (Protein kinase C family)PDK (Pyruvate dehydrogenase kinase isoform 1)CYP21A2 (Cytochrome P450 21-hydroxylase)TRAF3IP2 (Interleukin 17 pathway adaptor protein Act1)
Beyond the preview
Go deeper on danazol + iguratimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on danazol + iguratimod.